Search

Your search keyword '"Floriana Giorgio"' showing total 114 results

Search Constraints

Start Over You searched for: Author "Floriana Giorgio" Remove constraint Author: "Floriana Giorgio"
114 results on '"Floriana Giorgio"'

Search Results

1. Human Leukocyte Antigen (HLA) Haplotype Does Not Influence the Inflammatory Pattern of Duodenal Lymphocytosis Linked to Irritable Bowel Syndrome

2. Helicobacter pylori Primary and Secondary Genotypic Resistance to Clarithromycin and Levofloxacin Detection in Stools: A 4-Year Scenario in Southern Italy

3. The Puzzle of Coccoid Forms of Helicobacter pylori: Beyond Basic Science

4. Mucosal molecular pattern of tissue transglutaminase and interferon gamma in suspected seronegative celiac disease at marsh 1 and 0 stages

6. Helicobacter pylori clarithromycin resistance assessment: are gastric antral biopsies sufficient?

8. Might helicobacter pylori play a role in allergic or cross-reaction related disorders?

9. Possible role of nuclear factor erythroid 2-related factor 2 in the progression of human colon precancerous lesions

10. Helicobacter pylori Primary and Secondary Genotypic Resistance to Clarithromycin and Levofloxacin Detection in Stools: A 4-Year Scenario in Southern Italy

11. The Puzzle of Coccoid Forms of Helicobacter pylori: Beyond Basic Science

12. Curcumin and Colorectal Cancer: From Basic to Clinical Evidences

13. Chemoprevention of inflammation-related colorectal cancer by silymarin-, acetyl-11-keto-beta-boswellic acid-, curcumin- and maltodextrin-enriched dietetic formulation in animal model

14. New fecal test for non-invasive Helicobacter pylori detection: A diagnostic accuracy study

15. AF.23 HELICOBACTER PYLORI PRIMARY AND SECONDARY GENOTYPIC RESISTANCE TO CLARITHROMYCIN AND LEVOFLOXACIN DETECTION IN STOOLS: A 4-YEAR SCENARIO IN SOUTHERN ITALY

16. Noninvasive molecular analysis of Helicobacter pylori: Is it time for tailored first-line therapy?

19. Silymarin, boswellic acid and curcumin enriched dietetic formulation reduces the growth of inherited intestinal polyps in an animal model

20. Helicobacter pylori, liver cirrhosis, and portal hypertension: an updated appraisal

21. T05.02.12 MICROSCOPIC ENTERITIS ATTRIBUTABLE TO IRRITABLE BOWEL SYNDROME: CORRELATION BETWEEN INFLAMMATORY PATTERN, HLA STATUS, CLINICAL AND ENVIRONMENTAL FACTORS

22. Biological markers for non-celiac gluten sensitivity: a question awaiting for a convincing answer

23. New fecal test for non-invasive

24. Macronutrient intakes in obese subjects with or without small intestinal bacterial overgrowth: an alimentary survey

25. Seronegative Celiac Disease and Immunoglobulin Deficiency: Where to Look in the Submerged Iceberg?

26. Mucosal molecular pattern of tissue transglutaminase and interferon gamma in suspected seronegative celiac disease at marsh 1 and 0 stages

27. Regulation of apoptosis is impaired in atrophic gastritis associated with gastric cancer

28. Quadruple Rescue erapy aer First and Second Line Failure for Helicobacter pylori Treatment: Comparison between Two Tetracycline-Based Regimens

29. Mucosal Expression of Basic Fibroblastic Growth Factor, Syndecan 1 and Tumour Necrosis Factor-α in Crohn’s Disease in Deep Remission under Treatment with Anti-TNFα Antibodies

30. Change of point mutations in Helicobacter pylori rRNA associated with clarithromycin resistance in Italy

31. Expression of basic fibroblastic growth factor, syndecan 1 and tumour necrosis factor α in resected acute colonic diverticulitis

32. OC.10.3 SILYMARIN, BOSWELLIC ACID, CURCUMIN AND MALTODEXTRIN ENRICHED DIETETIC FORMULATION REDUCES THE GROWTH OF INHERITED INTESTINAL POLYPS IN AN ANIMAL MODEL

33. P.06.5 DQ 2 OR 8 HAPLOTYPE IN NON GLUTEN-RELATED MICROSCOPIC ENTERITIS IS NOT ASSOCIATED TO OVEREXPRESSION OF INFLAMMATORY AND INNATE IMMUNITY MARKERS

34. Effect of Probiotic or Prebiotic Supplementation on Antibiotic Therapy in the Small Intestinal Bacterial Overgrowth: A Comparative Evaluation

35. Helicobacter pylori DNA isolation in the stool: an essential pre-requisite for bacterial noninvasive molecular analysis

36. Role of concomitant therapy for

37. Letter: could sequential therapy extended to 14 days replace prolonged triple regimens for Helicobacter pylori treatment?

38. Musosal tumour necrosis factor α in diverticular disease of the colon is overexpressed with disease severity

39. PC.01.4: Isolation of Helicobacter Pylori Genetic Sequences in Fecal Samples: Non Invasive Molecular Analysis of Clarithromycin Susceptibility

40. Alrp, a survival factor that controls the apoptotic process of regenerating liver after partial hepatectomy in rats

42. Phenotypic and genotypic Helicobacter pylori clarithromycin resistance and therapeutic outcome: benefits and limits

43. Sequential vs. prolonged 14-day triple therapy for Helicobacter pylori eradication: the meta-analysis may be influenced by 'geographical weighting'

44. Detection of Helicobacter pylori DNA sequences in gastric biopsy samples to refine the diagnosis and therapy

45. Seronegative celiac disease: where is the specific setting?

46. Evolution of nonspecific duodenal lymphocytosis over 2 years of follow-up

47. Intestinal microbial metabolism of phosphatidylcholine: a novel insight in the cardiovascular risk scenario

48. DNA sequences and proteic antigens of H. pylori in cholecystic bile and tissue of patients with gallstones

49. A prospective trial in Saudi Arabia comparing the 14-day standard triple therapy with the 10-day sequential therapy for treatment of Helicobacter pylori infection: A further confirmation of 'Geographic Weight'

Catalog

Books, media, physical & digital resources